May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
COX-2 Promotes Intravitreal Neovascularization via a PGE2 / EP3 Receptor-dependent Mechanism
Author Affiliations & Notes
  • F. Sennlaub
    Dept of Ped Ophthalmology Pharm., Research Ctr St Justine Hospital, Montreal, PQ, Canada
  • A. Vazquez-Tello
    Dept of Ped Ophthalmology Pharm., Research Ctr St Justine Hospital, Montreal, PQ, Canada
  • D. Checchin
    Dept of Ped Ophthalmology Pharm., Research Ctr St Justine Hospital, Montreal, PQ, Canada
  • S. Brault
    Dept of Ped Ophthalmology Pharm., Research Ctr St Justine Hospital, Montreal, PQ, Canada
  • M. Beauchamp
    Dept of Ped Ophthalmology Pharm., Research Ctr St Justine Hospital, Montreal, PQ, Canada
  • F. Gobeil Jr
    Dept of Ped Ophthalmology Pharm., Research Ctr St Justine Hospital, Montreal, PQ, Canada
  • S. Chemtob
    Dept of Ped Ophthalmology Pharm., Research Ctr St Justine Hospital, Montreal, PQ, Canada
  • Footnotes
    Commercial Relationships  F. Sennlaub, None; A. Vazquez-Tello, None; D. Checchin, None; S. Brault, None; M. Beauchamp, None; F. Gobeil Jr, None; S. Chemtob, None.
  • Footnotes
    Support  Deutscher Akademischer Austausch Dienst
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2910. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Sennlaub, A. Vazquez-Tello, D. Checchin, S. Brault, M. Beauchamp, F. Gobeil Jr, S. Chemtob; COX-2 Promotes Intravitreal Neovascularization via a PGE2 / EP3 Receptor-dependent Mechanism . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2910.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)-2 promotes tumor angiogenesis. We investigated the role of COX-2 and specifically PGE2 and its receptors in ischemic proliferative retinopathy. Methods: The mouse and rat model of oxygen induced ischemic proliferative retinopathy were used. COX-2 and EP receptor expression were analysed by RT-PCR and Western blot analysis and their localization was studied by immunohistochemistry in the ischemic retina. Mice and rat pups undergoing the ischemic phase of the model were treated respectively with selective COX-2 inhibitors APHS and etodolac, alone or in conjunction with butaprost (EP2 agonist) or M&B;28767 (EP3 agonist) or treated with THG 213.15 (EP4 antagonist). Neovascularization was analyzed on flatmounts after 5 days of ischemia. VEGF and eNOS expression were analyzed in vehicle and COX-2 inhibitor-treated retinas by Western blot analysis. Results: COX-2 and EP 2, 3 and 4 (but not EP1) were equivalently expressed in whole retinas of normoxic and ischemic rodents. Immunohistochemical localization revealed increased COX-2 expression in retinal astrocytes during ischemia. EP3 was localized at the vascular endothelium. VEGF, known to be affected by PGE2, increased 8 h post-ischemia and returned to basal values by 24 h. APHS and etodolac effectively inhibited intravitreal neovascularization but not the percent of avascular area; COX-1 inhibitor SC560 was ineffective. Effects of COX-2 inhibition were reversed in part by simultaneous PGE2 injection and markedly by EP3 agonist M&B;28767, but not by modulation of EP2 and EP4 activity. eNOS, which mediates some of the effects of VEGF, was downregulated by 24 h treatment with etodolac. Conclusions: The proangiogenic effect of COX-2 in ischemic proliferative retinopathy is mainly mediated by PGE2 via activation of its EP3 receptor, which induces eNOS expression. COX-2 inhibitors may exert beneficial antiangiogenic effects in the ischemic proliferative retinopathy.

Keywords: neovascularization • ischemia • retinopathy of prematurity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×